Neuromod, the manufacturer of the Lenire Tinnitus Treatment system, has raised €10 million in equity financing to expand production of their unique neuromodulation device. The funding will support sustainable commercial growth in both Europe and the US.
The CE/FDA-approved Lenire device is already used by audiologists in 14 European countries and in over 100 independent clinics across the US. In June 2024, the company received a Federal Supply Schedule 65 II Medical Equipment and Supply Contract from the US government, making the device available to 2.9 million veterans with tinnitus through the USVA.
The Tinnitus Clinic Ltd was the first UK clinic to adopt the Lenire system, and our clinicians have extensive experience using the device to help reduce the impact of severe subjective tinnitus.
To learn more about how Lenire therapy can help with tinnitus, visit our page here.
